On-the-road driving performance after use of the antihistamines mequitazine and l-mequitazine, alone and with alcohol

N N J J M van der Sluiszen, A Vermeeren, S Jongen, E L Theunissen, A C M van Oers, C J Van Leeuwen, A Maret, C Desforges, A Delarue, J G Ramaekers

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
136 Downloads (Pure)

Abstract

OBJECTIVE: Previous studies demonstrated that mequitazine produces mild sedation after single doses. Its enantiomer, l-mequitazine, has a stronger potency for the H1 receptor. The aim of the current study was to assess the effects of l-mequitazine and mequitazine, alone and with alcohol, on driving.

METHODS: Twenty-five healthy volunteers were treated with l-mequitazine 2.5, 5.0 and 10 mg, mequitazine 10 mg and placebo, alone and in combination with alcohol in a double-blind crossover design. Driving performance was assessed using the standardized highway driving test in normal traffic. Its primary measure is the Standard Deviation of the Lateral Position (SDLP). Secondary measures consisted of an auditory word learning test during driving, and subjective measures of driving performance.

RESULTS: L-mequitazine 2.5 and 5.0 mg showed no effect on SDLP in the highway driving test, while SDLP significantly increased after l-mequitazine 10 mg (alone +1.59 cm; with alcohol +1.41 cm) and mequitazine 10 mg (with alcohol +1.17 cm). Alcohol significantly impaired all performance measures (SDLP +2.63 cm) but did not interact with the effects of treatment. Subjective measures indicated that participants were aware of the impairing effects of alcohol, but not of l-mequitazine and mequitazine.

CONCLUSION: L-mequitazine can be considered safe to drive in dosages of 2.5 and 5.0 mg. L-mequitazine 10 mg led to mild driving impairment. Alcohol impaired all performance measures and added to the effects of l-mequitazine and mequitazine.

Original languageEnglish
Pages (from-to)3461–3469
Number of pages9
JournalPsychopharmacology
Volume233
Issue number18
Early online date4 Aug 2016
DOIs
Publication statusPublished - Sep 2016

Keywords

  • Antihistamine
  • Alcohol
  • L-mequitazine
  • Mequitazine
  • Highway driving test
  • QUALITY-OF-LIFE
  • ALLERGIC RHINITIS
  • PSYCHOMOTOR PERFORMANCE
  • CETIRIZINE
  • COGNITION
  • SAFETY
  • DEXCHLORPHENIRAMINE
  • COMBINATION
  • PREVALENCE
  • VOLUNTEERS

Cite this

@article{78f7461352824b4196cd0717b5793b5a,
title = "On-the-road driving performance after use of the antihistamines mequitazine and l-mequitazine, alone and with alcohol",
abstract = "OBJECTIVE: Previous studies demonstrated that mequitazine produces mild sedation after single doses. Its enantiomer, l-mequitazine, has a stronger potency for the H1 receptor. The aim of the current study was to assess the effects of l-mequitazine and mequitazine, alone and with alcohol, on driving.METHODS: Twenty-five healthy volunteers were treated with l-mequitazine 2.5, 5.0 and 10 mg, mequitazine 10 mg and placebo, alone and in combination with alcohol in a double-blind crossover design. Driving performance was assessed using the standardized highway driving test in normal traffic. Its primary measure is the Standard Deviation of the Lateral Position (SDLP). Secondary measures consisted of an auditory word learning test during driving, and subjective measures of driving performance.RESULTS: L-mequitazine 2.5 and 5.0 mg showed no effect on SDLP in the highway driving test, while SDLP significantly increased after l-mequitazine 10 mg (alone +1.59 cm; with alcohol +1.41 cm) and mequitazine 10 mg (with alcohol +1.17 cm). Alcohol significantly impaired all performance measures (SDLP +2.63 cm) but did not interact with the effects of treatment. Subjective measures indicated that participants were aware of the impairing effects of alcohol, but not of l-mequitazine and mequitazine.CONCLUSION: L-mequitazine can be considered safe to drive in dosages of 2.5 and 5.0 mg. L-mequitazine 10 mg led to mild driving impairment. Alcohol impaired all performance measures and added to the effects of l-mequitazine and mequitazine.",
keywords = "Antihistamine, Alcohol, L-mequitazine, Mequitazine, Highway driving test, QUALITY-OF-LIFE, ALLERGIC RHINITIS, PSYCHOMOTOR PERFORMANCE, CETIRIZINE, COGNITION, SAFETY, DEXCHLORPHENIRAMINE, COMBINATION, PREVALENCE, VOLUNTEERS",
author = "{van der Sluiszen}, {N N J J M} and A Vermeeren and S Jongen and Theunissen, {E L} and {van Oers}, {A C M} and {Van Leeuwen}, {C J} and A Maret and C Desforges and A Delarue and Ramaekers, {J G}",
note = "Open Access",
year = "2016",
month = "9",
doi = "10.1007/s00213-016-4386-7",
language = "English",
volume = "233",
pages = "3461–3469",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer",
number = "18",

}

On-the-road driving performance after use of the antihistamines mequitazine and l-mequitazine, alone and with alcohol. / van der Sluiszen, N N J J M; Vermeeren, A; Jongen, S; Theunissen, E L; van Oers, A C M; Van Leeuwen, C J; Maret, A; Desforges, C; Delarue, A; Ramaekers, J G.

In: Psychopharmacology, Vol. 233, No. 18, 09.2016, p. 3461–3469.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - On-the-road driving performance after use of the antihistamines mequitazine and l-mequitazine, alone and with alcohol

AU - van der Sluiszen, N N J J M

AU - Vermeeren, A

AU - Jongen, S

AU - Theunissen, E L

AU - van Oers, A C M

AU - Van Leeuwen, C J

AU - Maret, A

AU - Desforges, C

AU - Delarue, A

AU - Ramaekers, J G

N1 - Open Access

PY - 2016/9

Y1 - 2016/9

N2 - OBJECTIVE: Previous studies demonstrated that mequitazine produces mild sedation after single doses. Its enantiomer, l-mequitazine, has a stronger potency for the H1 receptor. The aim of the current study was to assess the effects of l-mequitazine and mequitazine, alone and with alcohol, on driving.METHODS: Twenty-five healthy volunteers were treated with l-mequitazine 2.5, 5.0 and 10 mg, mequitazine 10 mg and placebo, alone and in combination with alcohol in a double-blind crossover design. Driving performance was assessed using the standardized highway driving test in normal traffic. Its primary measure is the Standard Deviation of the Lateral Position (SDLP). Secondary measures consisted of an auditory word learning test during driving, and subjective measures of driving performance.RESULTS: L-mequitazine 2.5 and 5.0 mg showed no effect on SDLP in the highway driving test, while SDLP significantly increased after l-mequitazine 10 mg (alone +1.59 cm; with alcohol +1.41 cm) and mequitazine 10 mg (with alcohol +1.17 cm). Alcohol significantly impaired all performance measures (SDLP +2.63 cm) but did not interact with the effects of treatment. Subjective measures indicated that participants were aware of the impairing effects of alcohol, but not of l-mequitazine and mequitazine.CONCLUSION: L-mequitazine can be considered safe to drive in dosages of 2.5 and 5.0 mg. L-mequitazine 10 mg led to mild driving impairment. Alcohol impaired all performance measures and added to the effects of l-mequitazine and mequitazine.

AB - OBJECTIVE: Previous studies demonstrated that mequitazine produces mild sedation after single doses. Its enantiomer, l-mequitazine, has a stronger potency for the H1 receptor. The aim of the current study was to assess the effects of l-mequitazine and mequitazine, alone and with alcohol, on driving.METHODS: Twenty-five healthy volunteers were treated with l-mequitazine 2.5, 5.0 and 10 mg, mequitazine 10 mg and placebo, alone and in combination with alcohol in a double-blind crossover design. Driving performance was assessed using the standardized highway driving test in normal traffic. Its primary measure is the Standard Deviation of the Lateral Position (SDLP). Secondary measures consisted of an auditory word learning test during driving, and subjective measures of driving performance.RESULTS: L-mequitazine 2.5 and 5.0 mg showed no effect on SDLP in the highway driving test, while SDLP significantly increased after l-mequitazine 10 mg (alone +1.59 cm; with alcohol +1.41 cm) and mequitazine 10 mg (with alcohol +1.17 cm). Alcohol significantly impaired all performance measures (SDLP +2.63 cm) but did not interact with the effects of treatment. Subjective measures indicated that participants were aware of the impairing effects of alcohol, but not of l-mequitazine and mequitazine.CONCLUSION: L-mequitazine can be considered safe to drive in dosages of 2.5 and 5.0 mg. L-mequitazine 10 mg led to mild driving impairment. Alcohol impaired all performance measures and added to the effects of l-mequitazine and mequitazine.

KW - Antihistamine

KW - Alcohol

KW - L-mequitazine

KW - Mequitazine

KW - Highway driving test

KW - QUALITY-OF-LIFE

KW - ALLERGIC RHINITIS

KW - PSYCHOMOTOR PERFORMANCE

KW - CETIRIZINE

KW - COGNITION

KW - SAFETY

KW - DEXCHLORPHENIRAMINE

KW - COMBINATION

KW - PREVALENCE

KW - VOLUNTEERS

U2 - 10.1007/s00213-016-4386-7

DO - 10.1007/s00213-016-4386-7

M3 - Article

C2 - 27488192

VL - 233

SP - 3461

EP - 3469

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 18

ER -